Non-small Cell Carcinoma Biomarker Testing: The Cytopathologist's Viewpoint
Abberly Lott Limbach, MD
University of Rochester
Many decisions about treatment in lung cancer are made on the basis of specific molecular and protein expression. This course is designed to give practicing cytopathologists a general introduction to the targeted therapy testing required for non-small cell lung carcinomas as well as a strategy to maximize limited specimens for several rounds of testing. In this course we will review the pre-analytical factors in specimen collection, from EBUS to biopsy to resection, and consider how specimen collection can affect testing. Finally, we will discuss several case examples alongside the targeted therapy testing followup and consider how to integrate targeted therapy testing into the cytopathologist's immediate assessment workflow.
This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.
- Discuss the most common types of targeted therapy testing for lung carcinoma, including PD-L1, EGFR, ALK, ROS1, RAS, and BRAF.
- Identify which pre-analytical factors affect targeted therapy testing and how tissue specimens are obtained.
- Develop a strategy for ordering targeted therapy tests using case examples.
Current ACCME guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect the speaker’s presentation(s). Therefore, it is the policy of the ASC to insure balance, independence, objectivity, and scientific rigor in all its educational programs. All planning individuals participating in any ASC Educational Activity are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. Click here for a complete list.
The presenter has no conflicts of interest or financial relationships to disclose.
ACCREDITATION AND DESIGNATION STATEMENTS
Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
American Board of Pathology Maintenance of Certification (MOC)
This product can help fulfill the CME requirements and Self-Assessment Modules (SAMs) mandated by the American Board of Pathology Maintenance of Certification (MOC) process. Earn up to 2.0 SAM Credit Hours.
Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians. The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the State of Florida and 1 in the State of California. The credit on each link is good for three years from the live presentation date.
- 2.00 AMA PRA Category 1 Credit™
- 1.00 California Credits
- 2.00 CMLE
- 2.00 Florida Credits
- 2.00 MOC II
- 2.00 Participant